Aeglea Biotherapeutics, Inc. (AGLE)
| Market Cap | 378.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -79.67M |
| Shares Out | 62.24M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $7.89 |
| Previous Close | $7.98 |
| Change ($) | -0.09 |
| Change (%) | -1.13% |
| Day's Open | 8.07 |
| Day's Range | 7.81 - 8.22 |
| Day's Volume | 243,329 |
| 52-Week Range | 3.51 - 11.04 |
AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benef...
Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inno...
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inno...
AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inno...
AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inn...
Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.
AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inn...
AUSTIN, Texas, Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innov...
AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics ...
Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics a...
Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is (AGLE) Outperforming Other Medical Stocks This Year?
If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...
Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics
AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as i...
Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis
Is (AGLE) Outperforming Other Medical Stocks This Year?
Find Strong Stocks During the Coronavirus with New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).
Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as s...
AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as d...
AUSTIN, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as ...
AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as s...
AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide so...
Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9 Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9
Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79%
Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3
The stock has gained 15% during the past month due to insider buying.
President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 31,905 shares of AGLE on 06/14/2019 at an average price of $6.16 a share.
Aeglea reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
About AGLE
Aeglea BioTherapeutics, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degra... [Read more...]
| Industry Biotechnology | IPO Date Apr 7, 2016 |
| CEO Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP | Employees 87 |
| Stock Exchange NASDAQ | Ticker Symbol AGLE |
Analyst Forecasts
According to 7 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 15.63, which is an increase of 98.10% from the latest price.